Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric risankizumab study in moderately to severely active Crohn's disease
NL-OMON59761Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of risankizumab in Crohn's disease, sponsored by AbbVie Inc. Primary endpoints: Maximum concentration, Time to maximum concentration and 3 more. Started Jul 2024; status: recruiting.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON59761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59761.